View filters (6 in use)

Updating results

494 results

Sort: Date | Relevance

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [ID1402]

In development [GID-TA10328] Expected publication date: TBC

Technology appraisal guidance In development

Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention

In development [GID-IPG10132] Expected publication date: 18 March 2020

Interventional procedures guidance In development

Artificial iris insertion for congenital aniridia

In development [GID-IPG10144] Expected publication date: 18 March 2020

Interventional procedures guidance In development

Artificial iris insertion for acquired aniridia

In development [GID-IPG10130] Expected publication date: 18 March 2020

Interventional procedures guidance In development

Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

In development [GID-NG10113] Expected publication date: 12 May 2021

NICE guideline In development

Galcanezumab for preventing migraine [ID1372]

In development [GID-TA10454] Expected publication date: 14 October 2020

Technology appraisal guidance In development

Chronic kidney disease: assessment and management (update)

In development [GID-NG10118] Expected publication date: 18 March 2021

NICE guideline In development

Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Highly specialised technologies guidance In development

Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

In development [GID-TA10164] Expected publication date: TBC

Technology appraisal guidance In development

Cardiac transplantation (rejection) - everolimus [ID114]

In development [GID-TAG232] Expected publication date: TBC

Technology appraisal guidance In development

Postnatal care

In development [GID-NG10070] Expected publication date: 25 November 2020

NICE guideline In development

Multiple sclerosis (primary-progressive) - fingolimod [ID62]

In development [GID-TAG221] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - ximelagatran [ID376]

In development [GID-TAG377] Expected publication date: TBC

Technology appraisal guidance In development

Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466

In development [GID-TA10355] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264

In development [GID-TA10365] Expected publication date: TBC

Technology appraisal guidance In development

Shared decision making

In development [GID-NG10120] Expected publication date: 14 April 2021

NICE guideline In development

Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)

In development [GID-TA10366] Expected publication date: 18 November 2020

Technology appraisal guidance In development

Babies, children and young people's experience of healthcare

In development [GID-NG10119] Expected publication date: 07 April 2021

NICE guideline In development

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Technology appraisal guidance In development

Eltrombopag for untreated severe aplastic anaemia ID1198

In development [GID-TA10284] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

In development [GID-TA10338] Expected publication date: TBC

Technology appraisal guidance In development

Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Technology appraisal guidance In development

Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413

In development [GID-TA10329] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357

In development [GID-TA10322] Expected publication date: TBC

Technology appraisal guidance In development

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Technology appraisal guidance In development

Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260

In development [GID-TA10309] Expected publication date: TBC

Technology appraisal guidance In development

Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Technology appraisal guidance In development

Safeguarding adults in care homes

In development [GID-NG10107] Expected publication date: 21 October 2020

NICE guideline In development

Moxetumomab pasudotox for hairy-cell leukaemia [ID1142]

In development [GID-TA10288] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

In development [GID-TA10295] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

In development [GID-TA10394] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

In development [GID-TA10380] Expected publication date: TBC

Technology appraisal guidance In development

Neonatal parenteral nutrition

In development [GID-NG10037] Expected publication date: 26 February 2020

NICE guideline In development

Heart valve disease presenting in adults: investigation and management

In development [GID-NG10122] Expected publication date: 20 May 2021

NICE guideline In development

Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 04 April 2022

NICE guideline In development

Antenatal care for uncomplicated pregnancies update

In development [GID-NG10096] Expected publication date: 21 April 2021

NICE guideline In development

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 August 2020

Technology appraisal guidance In development

Fetoscopic prenatal repair for open neural tube defects in the fetus

In development [GID-IPG10120] Expected publication date: 29 January 2020

Interventional procedures guidance In development

Open prenatal repair for open neural tube defects in the fetus

In development [GID-IPG10140] Expected publication date: 29 January 2020

Interventional procedures guidance In development

Patiromer for treating hyperkalaemia [ID877]

In development [GID-TA10273] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Highly specialised technologies guidance In development

Siponimod for treating secondary progressive multiple sclerosis [ID1304]

In development [GID-TA10436] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Caesarean section (Update)

In development [GID-NG10081] Expected publication date: 21 January 2021

NICE guideline In development

Balloon dilation for eustachian tube dysfunction

In development [GID-IPG10125] Expected publication date: 18 December 2019

Interventional procedures guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 05 June 2020

Technology appraisal guidance In development

Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer [ID1665]

In development [GID-TA10550] Expected publication date: TBC

Technology appraisal guidance In development

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

In development [GID-TA10526] Expected publication date: TBC

Technology appraisal guidance In development

KTE-X19 for treating relapsed or refractory mantle cell lymphoma ID1313

In development [GID-TA10312] Expected publication date: 06 December 0021

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development